Intestinal Dysbiosis: A Common Precursor To Inguinal Hernia

Digestive System: Intestinal Dysbiosis And The Causes Of Disease


Leo Galland MD, FACN , Stephen Barrie ND ©

ABSTRACT : With the advent of biochemical and microbial stool analysis panels, an increasing number of physicians are seeking a clearer understanding of the relationship between the ecology of the digestive tract and local and systemic factors affecting health and disease. Dysbiosis is a state of living with intestinal flora that has harmful effects. It can be described as being due to either putrefaction, fermentation, deficiency, or sensitization. A number of inflammatory diseases within the bowel or involving skin and connective tissue have been reported in association with dysbiosis. This article details the relationships, causes and treatment options for dysbiotic related conditions.

Recognition that intestinal flora have a major impact on human health first developed with the birth of microbiology in the late nineteenth century. It is generally accepted that our relationship with indigenous gut flora is “Eu-symbiotic,” meaning a state of living together that is beneficial. Metchinkoff popularized the idea of “Dys-symbiosis, or Dysbiosis,” a state of living with intestinal flora thathas harmful effects. He postulated that toxic amines produced by bacterial putrefaction of food were the cause of degenerative diseases, and that ingestion of fermented foods containing Lactobacilli could prolong life by decreasing gut putrefaction(1). Although Metchnikoff’s ideas have been largely ignored in the United States, they have influenced four generations of European physicians. The notion that dysbiotic relationships with gut microflora may influence the development of inflammatory diseases and cancer has received considerable experimental support over the past two decades, but the mechanisms involved are far more diverse than Metchnikoff imagined.

The stool of healthy human beings consuming a Western diet contains 24 x 105¡ bacteria/gram. Twenty species comprise 75% of the total number of colonies; non-spore forming anaerobes predominate over aerobes by a ratio of 5000:1(2). Organisms cultured from mucosal surfaces are significantly different from those found in stool and vary among different parts of the gastrointestinal tract. The bacterial concentration in the stomach and small intestine is several orders of magnitude less than in the colon. The major mucosal organisms there are coccobacilli(1) and streptococci(3). The predominant organisms cultured from gastric and duodenal aspirates, are yeasts and Lactobacilli(2), living in the lumen. In the colon, the presence of these organisms is overshadowed by spirochetes and fusfform bacteria on the mucosal surface and anaerobic rods like Eubacterium, Bacteroides and Bifidobacterium in the lumen. Benefits and adverse effects of the normal gut microflora are listed in Table 1 & 2 and have been described elsewhere(4).

Materials and Methods

Clinical Assessment
lntestinal dysbiosis should be considered as a mechanism promoting disease in all patients with chronic gastrointestinal, inflammatory or autoimmune disorders, food allergy and intolerance, breast and colon cancer, and unexplained fatigue, malnutrition or neuropsychiatric symptoms.

The most useful test for this condition is a Comprehensive Digestive Stool Analysis (CDSA) which includes:

a) biochemical measurements of digestion/maldigestion (fecal chymotrypsin, fecal triglycerides, meat and vegetable fibers, pH), intestinal absorption/ malabsorption (long chain fatty acids, fecal cholesterol, and total short chain fatty acids)
b) metabolic markers of intestinal metabolism
c) identification of the bacterial microflora, including friendly, pathogenic and imbalanced flora
d) detection of abnormal gut mycology

The authors have developed a Gut Dysbiosis Score (Table 3) to make the CDSA more useful.

Interpretation of Gut Dysbiosis Score (Refers to Table 3)

Excess meat or vegetable fibers or triglycerides (one point each) suggest mal- digestion. This is a common effect of bacterial overgrowth but can also con- tribute to its cause.

Excess cholesterol or fatty acids (one point each) is indicative of malabsorp- tion; bacterial overgrowth produces this by interfering with micelle forma- tion.

Low concentrations of butyrate or SCFA (two points each) indicate insuffi- cient anaerobic fermentation of soluble fiber. This may result from a low fiber diet deficiency of Bifidobacteria.

High concentrations of butyrate or SCFA (two points each) is indicative of increased anaerobic fermentation.

Alkaline stool pH (two points) often accompanies a low butyrate. When it is associated with a normal butyrate it signifies increased ammonia production, reflecting a diet high in meat or excessive urease activity of intestinal bacte- ria. Bacterial cultures can provide more direct evidence of dysbiosis. The most common finding is:

A lack of Lactobacillus or of E.Coli on stool culture (3 points each) High levels of uncommon or atypical Enterobacteriaceae or of Klebsiella, Proteus or Pseudomonas, may reflect small bowel overgrowth of these organisms (score 1 point for each.)

Total Score-7 points or more is always associated with clinical dysbiosis; 5-6 is probable dysbiosis; 3-4 is borderline. There are rare cases in which a score less than 3 occurs in a dysbiotic stool. These cases are usually under treatment at the time the stool is obtained. In severe cases abnormal blood tests may be found. There may be erythrocyte macrocytosis, low circulating vitamin B12 or hypoalbuminemia. Urinary excretion of essential amino acids may also be low, signifying impaired assimilation of dietary protein.

Based on available research and clinical data, we now believe that there are four patterns of intestinal dysbiosis: putrefaction, fermenta- tion, deficiency, and sensitization.

This is the classic Western degenerative disease pattern advanced by Metchnikoff. Putrefaction dysbiosis results from diets high in fat and animal flesh and low in insoluble fiber. This type of diet produces an increased concentration of Bacteroides sp. and a decreased concentra- tion of Bifidobacteria sp. in stool. It increases bile flow and induces bacterial urease activity(1). The alterations in bacterial population dynamics which result from this diet are not measured directly by the [Comprehensive Digestive Stool Analysis (CDSA)]. The changes occur primarily among anaerobes, but the effects are measured in an in- crease in stool pH (partly caused by elevated ammonia production) and in bile or urobilinogen and possibly by a decrease in short chain fatty acids, especially in butyrate. Epidemiologic and experimental data implicate this type of dysbiosis in the pathogenesis of colon can- cer and breast cancer(6). A putrefaction dysbiosis is accompanied by an increase in fecal concentrations of various bacterial enzymes which metabolize bile acids to tumor promotors and deconjugate ex- creted estrogens, raising the plasma estrogen level(6). Putrefaction dysbiosis is corrected by decreasing dietary fat and flesh, increasing fiber consumption and feeding Bifidobacteria and Lactobacillus prep- arations.

Most adverse effects of the indigenous gut flora are caused by the intense metabolic activity of luminal organisms. The following are associated with Putrefaction dysbiosis:

1. The enzyme urease, found in Bacteroides, Proteus and Klebsiella species, and induced in those organisms by a diet high in meat, hy- drolyzes urea to ammonia, raising stool pH. A relatively high stool pH is associated with a higher prevalence of colon cancer(7).

2. Bacterial decarboxylation of amino acids yields vasoactive and neurotoxic amines, including histamine, octopamine, tyramine and tryptamine; these are absorbed through the portal circulation and deaminated in the liver. In severe cirrhosis they reach the systemic circulation and contribute to the encephalopathy and hypotension of hepatic failure(1).

3. Bacterial tryptophanase degrades tryptophan to carcinogenic phe- nols, and, like urease, is induced by a high meat diet(8).

4. Bacterial enzymes like beta-glucuronidase hydrolyze conjugated es- trogens and bile acids. Hepatic conjugation and biliary excretion is an important mechanism for regulating estrogen levels in the body. Bacte- rial deconjugation increases the enterohepatic recirculation of estrogen. A Western diet increases the level of deconjugating enzymes in stool, lowers estrogen levels in stool and raises estrogen levels in blood and urine, possibly contributing to the development of breast cancer(6).

5. Beta-glucuronidase and other hydrolytic bacterial enzymes also deconjugate bile acids.

Deconjugated bile acids are toxic to the colonic epithelium and cause diarrhea. They or their metabolites appear to be carcinogenic and are thought to contribute to the development of colon cancer(6,9) and to ulcerative colitis(10). Gut bacteria also reduce primary bile acids like cholate and chenodeoxycholate to secondary bile acids like deoxycholate (DCA) and lithocholate. The secondary bile acids are ab- sorbed less efficiently than primary bile acids and are more likely to contribute to colon carcinogenesis. The prevalence of colon cancer is proportional to stool concentration of DCA.

Not all bacterial enzyme activity is harmful to the host. Fermenta- tion of soluble flber by Bifidobacteria sp. yields SCFA. Recent interest has focused on the beneficial role of short-chain fatty acids like buty- rate in nourishing healthy colonic mucosal cells. Butyrate has been shown to induce differentiation of neoplastic cells(l1), decreased ab- sorption of ammonia from the intestine(1), decreased inflammation in ulcerative colitis(12) and, following absorption, decreased cholesterol synthesis in the liver(7). Butyrate lowers the stool pH. A relatively low stool pH is associated with protection against colon cancer(S). The principal source of colonic butyrate is fermentation of soluble fiber by colonic anaerobes. Thus, putrefaction dysbiosis results from the inter- play of bacteria and diet in their effects on health and disease.

This is a condition of carbohydrate intolerance induced by overgrowth of endogenous bacteria in the stomach, small intestine and cecum. The causes and effects of small bowel bacterial overgrowth have been well characterized.

Bacterial overgrowth is promoted by gastric hypochlorhydria, by stasis due to abnormal motility, strictures, fistulae and surgical blind loops, by immune deficiency or by malnutrition( 13). Small bowel parasitosis may also predispose to bacterial overgrowth(4). Some of the damage resulting from small bowel bacterial overgrowth is pro- duced by the action of bacterial proteases which degrade pancreatic and intestinal brush border enzymes causing pancreatic insufficiency, mucosal damage and malabsorption. In more severe cases the intesti- nal villi are blunted and broadened and mononuclear cells infiltrate the lamina propria. Increased fecal nitrogen leads to hypoalbumine- mia. Bacterial consumption of cobalamin lowers blood levels of vita- min B12. Bile salt dehydroxylation impairs micelle formation(10). Endotoxemia resulting from bacterial overgrowth contributes to hep- atic damage in experimental animals(14).

Gastric bacterial overgrowth increases the risk of systemic infec- tion. Gastric bacteria convert dietary nitrates to nitrites and nitro- samines; hence, the increased risk of gastric cancer in individuals with hypochlorhydria( 15) . Some bacterial infections of the small bowel increase passive intestinal permeability(16).

Carbohydrate intolerance may be the only symptom of bacterial overgrowth, making it indistinguishable from intestinal candidosis; in either case dietary sugars can be fermented to produce endogenous ethanol(17,18). Chronic exposure of the small bowel to ethanol may itself impair intestinal permeability(19). Another product of bacterial fermentation of sugar is D-lactic acid. Although D-lactic acidosis is usually a complication of short-bowel syndrome or of jejuno-ileal by- pass surgery (colonic bacteria being the source of acidosis), elevated levels of D-lactate were found in blood samples of 1.12% of randomly selected hospitalized patients with no history of gastro-intestinal sur- gery or disease(20). Small bowel fermentation is a likely cause of D-lactic acidosis in these patients. British physicians working with the gut-fermentation syndrome as described by Hunisett et al(18) have tentatively concluded, based on treatment results, that the ma- jority of cases are due to yeast overgrowth and about 20% are bacte- rial in origin. The symptoms include abdominal distension, carbohy- drate intolerance, fatigue and impaired cognitive function.

Exposure to antibiotics or a diet depleted of soluble fiber may create an absolute deficiency of normal fecal flora, including Bifidobacteria, Lactobacillus and E. Coli. Direct evidence of this condition is seen on stool culture when concentrations of Lactobacillus or E. Coli are re- duced. Low fecal short chain fatty acids provide presumptive evi- dence. This condition has been described in patients with irritable bowel syndrome and food intolerance (see below). Deficiency and pu- trefaction dysbiosis are complementary conditions which often occur together and have the same treatment.

Aggravation of abnormal immune responses to components of the normal indigenous intestinal microflora may contribute to the patho- genesis of inflammatory bowel disease, spondyloarthropathies, other connective tissue disease and skin disorders like psoriasis or acne. The responsible bacterial components include endotoxins, which can activate the alternative complement pathway and antigens, some of which may cross react with mammalian antigens. Treatment studies in ankylosing spondylitis and inflammatory bowel disease suggest that sensitization may complement fermentation excess and that sim- ilar treatments may benefit both conditions.

Clinical research has implicated bacterial dysbiosis in a number of diseases of inflammation within the bowel or involving skin or con- nective tissue. The published associations are reviewed below:

Atopic Eczema
Ionescu and his colleagues have studied fecal and duodenal flora in patients with atopic eczema and found evidence of small bowel dys- biosis and subtle malabsorption phenomena in the majority(21,22). Treatment with antibiotics or with a natural antibiotic derived from grapefruit seeds, produced major improvement in the gastro-intesti- nal symptoms of eczema patients and moderate improvement in se- verity of eczema(23). One advantage in the use of grapefruit seed ex- tract over conventional antibiotics lies in its anti-fungal activity. This agent adds a second therapeutic dimension and eliminates the possi- bility of secondary candidosis. The minimum effective dose of grape- fruit seed extract for bacterial dysbiosis is 600 mg a day.

Irritable Bowel Syndrome
Hunter and his colleagues have studied patients with the irritable bowel syndrome in whom diarrhea, cramps and specific food intol- erances are major symptoms(24). They have found abnormal fecal flora to be a consistent finding, with a decrease in the ratio of anaer- obes to aerobes, apparently due to a deficiency of anaerobic flora (25,26). Previous exposure to antibiotics, metronidazole in particular, was associated with the development of this disorder(27). There are treatments for this, such as consuming more soluble fibre, cut down on high-fibre foods, there are various medications to also support the pain. In addition to this, there is also Hypnotherapy for IBS which is also worthwhile looking into. It is important to weigh up which solution suits your needs best.

Inflammatory Bowel Disease
Two decades ago, exaggerated immunologic responses to components of the normal fecal flora were proposed as possible mechanisms in the etiology of inflammatory bowel disease(28). Little progress has been made in confirming or disproving this theory, although bacterial overgrowth of the jejunum has been found in 30% of patients hospi- talized for Crohn’s disease, in which it contributes to diarrhea and malabsorption(29).

The demonstration of increased intestinal permeability in patients with active Crohn’s disease and in healthy first degree relatives sug- gests the existence of a pre-existing abnormality that allows an exag- gerated immune response to normal gut contents to occur(30).

It is interesting to note that elemental diets can induce remission in Crohn’s disease as effectively as prednisone. The chief bacteriologic effect of elemental diets is to lower the concentration of Lactobacilli in stool drastically without altering levels of other bacteria(31). It is well-known that many patients with Crohn’s disease can be brought into remission with metronidazole, tetracycline and other antibiotics. In ulcerative colitis, colonic damage from toxic metabolites of bile acids has been suggested(9). Alpha-tocopherylquinone, a vitamin E derivative that antagonizes vitamin K dependent bacterial enzymes reversed ulcerative colitis dramatically in one subject(32).

Drawing on much broader experience with inflammatory bowel dis- ease, Gottschall has proposed that gut dysbiosis plays the major etiologic role, with small and large bowel fermentation being a key component. She has used a specific carbohydrate diet restricted in disaccharide sugars and devoid of cereal grains to alter gut flora(33). Some will undoubtedly argue that Gottschall’s success is due to food allergen elimination, but the time course of patients’ responses is more consistent with the authors’ contention that a gradual alter- ation of gut flora content is the mechanism.

McCann has pioneered a dramatic, experimental treatment for in- flammatory bowel disease which has induced a rapid remission in 16 out of 20 patients with ulcerative colitis. A two-day course of multi- ple-broad spectrum antibiotics to “decontaminate” the gut is followed by administration of defined strains of E. coli, and Lactobacillus ac- idophillus to produce a “reflorastation” of the colon(34).

Arthritis and Ankylosing Spondylitis
Immunologic responses to gut flora have been advanced by several authors as important factors in the pathogenesis of inflammatory joint diseases. It is well-known that reactive arthritis can be acti- vated by intestinal infections with Yersinia, Salmonella and other enterobacteria(35). In some cases bacterial antigens have been found in synovial cells(36,37) and may enter the circulation because of the increased intestinal permeability associated with the intestinal infec- tion(l5). Increased intestinal permeability and immune responses to bacterial debris may cause other types of inflammatory joint disease as well. but there is little evidence of the frequency with which this occurs(38-40). Several groups have proposed a specific mechanism by which Klebsiella pneumoniae may provoke ankylosing spondylitis (41-43). HLA-B27 is expressed on the lymphocytes and synovial cells of 97% of patients with ankylosing spondylitis. This antigen cross- reacts with antigens found on Klebsiella pneumoniae and possibly other enterobacteria. Patients with ankylosing spondylitis have higher levels of Klebsiella pneumoniae in their stools than controls and have higher levels of anti-Klebsiella IgA in plasma than do con- trols. Patients who are HLA-B27 positive but who do not have an- kylosing spondylitis do not have Klebsiella in their stools or Kleb- siella antibodies in their plasma.

Molecular mimicry appears to be the mechanism by which intesti- nal enterobacteria cause ankylosing spondylitis in genetically suscep- tible individuals.

Ebringer has successfully treated ankylosing spondylitis with a low starch diet similar to Gottschall’s regimen for bowel disease. This diet lowers the concentration of Klebsiella in stool and decreases the titre of anti-Klebsiella IgA. He has also proposed that rheumatoid ar- thritis, which is associated with HLA-DR4, involves a similar molecu- lar mimicry between HLA-DR4 and Proteus mirabilis, as cross-reac- tive Proteus antibodies are higher in patients with rheumatoid arthritis than in controls. Abnormal immune responses to compo- nents of the normal gut flora represents a form of dysbiosis which suggests novel treatment for inflammatory diseases. Those suffering from AS may want to consider trying a form of ankylosing spondylitis physical therapy which could help to slow the disease’s progression and improve their quality of life. With no known cure, physical therapy is the first line of treatment for the condition helping to improve patients’ posture and mobility as well as reduce pain and discomfort.

Treatment Approaches
Diet-Putrefaction dysbiosis is usually managed with a diet high in both soluble and insoluble fiber and low in saturated fat and animal protein. Dairy products have a variable effect. Fermented dairy foods like fresh yogurt are occasionally helpful. These dietary changes work to lower the concentrations of Bacteroides and increase concen- trations of lactic acid-producing bacteria (Bifidobacteria, Lactobacil- lus and lactic acid streptococci) in the colon(44,45). Supplementing the diet with defined sources of fiber can have variable effects on colo- nic dysbiosis. Insoluble fiber decreases bacterial concentration and microbial enzyme activity(46,47). Soluble fiber, on the other hand, tends to elevate bacterial concentration and enzyme activity at the same time that it raises the levels of beneficial short chain fatty acids. This disparity may explain the superior effect of insoluble fiber in the prevention of colon cancer(48-51). Fructose-containing oligosac- charides, found in vegetables like onion and asparagus, have been developed as a food supplement for raising stool levels of Bifidobac- teria and lower stool pH.(52)

In fermentation dysbiosis, by contrast, starch and soluble fiber may exacerbate the abnormal gut ecology(3,33). When the upper small bowel is involved, simple sugars are also contra-indicated. A diet free of cereal grains and added sugar is generally the most helpful. Fruit, fat and starchy vegetables are tolerated to variable degree in differ- ent cases. Oligosaccharides found in some vegetables, carrots in par- ticular, inhibit the binding of enterobacteria to the intestinal mucosa. Carrot juice and concentrated carrot oligosaccharides have been used in Europe for bacterial diarrhea for almost a century(53). BiotherapiesÑAdministration of bacteria indigenous to the healthy human colon can reverse relapsing Clostridium difficile infection(54). Lactobacillus administration has long been used in an attempt to im- prove gut microbial ecology. Regular ingestion of acidophilus milk lowers stool concentrations of urease-positive organisms and of bacte- rial enzymes which may contribute to carcinogenesis(55). Fermented dairy products and Iyophilized Lactobacillus preparations have been shown to be useful in treating and preventing salmonellosis, shig- ellosis, antibiotic-induced diarrhea and in inhibiting tumor growth (56). Problems with Lactobacilli include the failure of organisms to adhere to the intestinal mucosa or to survive damage from gastric acid and bile. The acidophilus sweepstakes has led to the search for newer and better strains for medical uses(57,58).

Bifidobacteria are the predominant lactic acid bacteria of the colon with a concentration that is 1000 times higher than Lactobacilli. Ad- ministration of Bifidobacterium brevum to humans and animals re- duces fecal concentrations of Clostridia and Enterobacter species, am- monia, and toxigenic bacterial enzymes including beta-glucuronidase and tryptophanase; urinary indican is also lowered(59). Administra- tion of defined strains of E. coli and Enterococcus for the purpose of altering gut flora has been popular in Europe, but documentation of the health effects is scanty.

Bacillus laterosporus, a novel organism classified as non patho- genic to humans(60), produces unique metabolites with antibiotic, anti-tumor and immune modulating activity(61-63). This organism has been available as a food supplement in the United States for about 5 years. We have found it to be an effective adjunctive treat- ment for control of symptoms associated with small bowel dysbiosis in a number of patients.

Of equal interest, and more thoroughly researched, a yeast, Sac- charomyces boulardii, has been used in Europe for control of non- specific diarrhea for several decades. Originally isolated from Indo- chinese leechee nuts, S. boulardii is grown and packaged as a medica- tion in France, where it is popularly called, “Yeast Against Yeast”. Controlled studies have demonstrated its effectiveness in preventing antibiotic associated diarrhea and Clostridium difficile colitis(64,65). S. boulardii has also been shown to stimulate production of secretory IgA in rats(66). Immune enhancing therapy of this type may be con- traindicated in patients suffering from reactive arthritis and other diseases in which an exaggerated intestinal immune response is found.

Antibiotic drugs may either cause or help control dysbiosis, depending upon the drug and the nature of the disorder. Some drugs may not work due to how a body metabolizes them, this is where websites such as can be of assistance in testing the human bodies reaction to certain drugs and seeing if they have any effect. Where contamination of the small bowel by anaerobes is the problem, metronidazole or tetracyclines may be beneficial. When enterobacterial overgrowth predominates, ciprofloxacin is usually the drug of choice because it tends to spare anaerobes. Herbal antibiotics may be preferred because of their greater margin of safety and the need for prolonged anti- microbial therapy in bacterial overgrowth syndromes. Citrus seed ex- tract may be a desirable first line of treatment because of its broad spectrum of antibacterial, anti-fungal and anti-protozoan effects(23). The usual dose required is 600 to 1600 mg/day. Animal studies have shown no toxicity except for intestinal irritation producing diarrhea at very high doses. The mechanism of action is not known; there is no evidence of systemic absorption. Bayberry leaf, containing the alka- loid berberine, appears to be cidal for enterobacteria, yeasts and amoebae. The control of dysbiotic symptoms usually requires several grams a day. Artemesia annua has primarily been used for treatment of protozoan infection(67). The most active ingredient, artemisinin, is a potent pro-oxidant whose activity is enhanced by polyunsaturated fats like cod liver oil and antagonized by vitamin E.(68). Artemisinin is used intravenously in Southeast Asia for the treatment of cerebral malaria; it has no known side effects except for induction of abortion when used at high doses in pregnant animals.

The herbal pharmacopeia lists many substances with natural anti- biotic activity and the potential for herbal treatment of gut dysbiosis is virtually unlimited. A tannin-rich mixture of herbal concentrates including extracts of gentiana, sanguinaria and hydrastis has been marketed under various names. In vitro studies at Great Smokies Di- agnostic Laboratory have found this mixture to exert more potent ac- tivity against enterobacteriaceae and Staphylococcus than any of the common antibiotic drugs tested; its major side effect is nausea pro- duced by the high tannin content.

Summary and Conclusions
Altered microbial ecology in the gut may produce disease and dys- function because of the intense metabolic activity and antigenicity of the bacterial flora. Bacterial enzymes can degrade pancreatic en- zymes, damage the intestinal brush border, deconjugate and reduce bile acids and alter the intestinal milieu in numerous ways, some of which can be easily measured in a properly collected sample of stool. Bacterial antigens may elicit dysfunctional immune responses which contribute to autoimmune diseases of the bowel and of connective tissue. Effective treatment of dysbiosis with diet, antimicrobial sub- stances and biotherapies must distinguish among patterns of dys- biosis. The failure of common approaches utilizing fiber and Lacto- bacilli is a strong indication of small bowel bacterial overgrowth, a challenging disorder which demands a radically different approach.


l. Mentioned in Brown JP. Role of gut bacterial flora in nutrition and health: a review of recent advances in bacteriological techniques, metabolism and factors affecting flora composition. CRC Rev Food Sci Nutr 1977 8:229-336.
2. Haenel H, Bendig J. Intestinal flora in health and disease. Prog Food Nutr Sci 1975, 1:21-64.
3. Berghouse L, Hon S, Hill M, et al. Comparison between the bacterial and oligosaccharide content of ileostomy effluent in subjects taking diets rich in refined or unrefined carbohydrate. Gut 1984; 25:1071-1077.
4. Galland L. Effects of intestinal microbes on systemic immunity. Post Viral Fatigue
Syndrome, Mowbray P, Jenkins R eds. John Wiley & Sons, London, 1991; 405430.
5. Newmark HL, Lupton JR. Determinants and consequences of colonic luminal pH: implications for colon cancer. Nutr and Cancer 1990; 14:161-173. 6. Goldin BR. The metabolism of the intestinal microflora and its relationship to di- etary tat, colon and breast cancer. Dietary Fat and Cancer New York, Alan R. Liss 1986 655-685.
7. Malhotra SL. Fecal urobilinogen levels and pH of stools. J Royal Soc Med 1982; 75:710.
8. Chung K-T, Fulk GE, Slein MW. Tryptophanase of fecal flora as a possible factor in the etiology of colon cancer. J Natl Can Inst 1975, 54:1073-1078.
9. Hill MJ, Melviulle DM, LennardÇJones JE, Neale K, Ritchie JK. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis. Lancet 1987; 2:185-186.
10. Bennet JD. Ulcerative colitis: the result of an altered bacterial metabolism of bile acids or cholesterol. Med Hypoth 1986, 20:125-132.
11. Effects of short-chain fatty acids on a human colon carcinoma cell line. Nutr Rev (United States) 1988; 46(1):11-12.
12. Breuer Rl. Rectal irrigation with short-chain fatty acids. Dig Dis Sci 1991; 2:185-187.
13. Kistler LA, Gianella RA. Relationship of intestinal bacteria to malabsorption. Pract Gastroenterol 1980; 4:24-44.
14. Lichtman SN, Keku J, Schwab JH, Sartor RB. Hepatic injury associated with small bowel bacterial overgrowth in rats is prevented by metronidazole and tetra- cycline. Gastroenterol 1991; 100:513-519.
15. du Moulin GC, Hedley-White J. The stomach as a bacterial reservoir: clinical significance. IM: Internal Medicine for the Specialist 1982; 3:47-55.
16. Serrander R, Magnusson K-E, Kihlstrom E, Sundqvist T. Acute yersinia infections in man increase intestinal permeability for low-molecular weight polyethylene glycols (PEG 400). Scand J Inf Dis 1986, 18:409-412.
17. Bode JC, Rust S, Bode C. The effect of cimetidine treatment on ethanol formation in the human stomach. 9and J Gastroenterol 1984; 19:853-856.
18. Hunnisett A, Howard J, Davies S. Gut fermentation (or the auto-brewery) syn- drome: a new clinical test with initial observations and discussion of clinical and biochemical implications. J Nutr Med 1990; 1:33-38.
19. Sudduth WH. The role of bacteria and enterotoxemia in physical addiction to alcohol. Microecology and Therapy 1989; 18: 77-81.
20. Thurn JR, Pierpont GL, Ludvigsen CW, Eckfeldt JH. D-lactate encephalopathy. Am J Med 1985; 79:717-721.
21. Ionescu G, Kiehl R, Ona L, Schuler R. Abnormal fecal microflora and malabsorption phenomena in atopic eczema patients. J Adv Med 1990; 3:71-89.
22. Ionescu G, Kiehl R, Wichmann-Kunz F, Leimbeck R. Immunobiological significance of fungal and bacterial infections in atopic eczema. J Adv Med 1990; 3:47-58.
23. Ionescu G, Kiehl R, Wichmann-Kunz F, Williams C, et al. Oral citrus seed extract in atopic eezema: In vitro and in vivo studies on intestinaˆ microflora. J Orthomoˆ Med 1990, 5:155-161.
24. Alun Jones V, Shorthouse M, McLaughlin P, et al. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. Lancet 1980 2:1115-1117.
25. Bayhss CE, Bradley HK, Alun Jones V, Hunter JO. Some aspects of colonic microblal actlvlty in irritable bowel syndrome associated with food intolerance. Annalidell Istituto Superiore di Sanita 1986, 22:959-964.
26. Hunter JO, Alun Jones V. Studies on the pathogenesis of irritable bowel svndrome produced by food intolerance. Read NW, ed, The Irritable Bowel Syndro;ne, New York, Grune and Stratton, 1985; 185-190.
27. Alun Jones V, Wilson AJ, Hunter JO, Robinson RE. The aetiological role of antibilotgi8c4pr5o/phYlalxli)ssw2ith hysterectomy in irritable bowel syndrome J Ob and Gyn
28. Shorter RG, Huizenga KA, Spencer BJ. A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease. Digest Dis 1972;
29. Beeken WL. Remedial defects in Crohn disease. Arch Int Med 1975, 135:686-690.
30. Hollander D, Vadheim C, Brettholz E, et al. Increased intestinal permeabilitv in patients with Crohn’s disease and their relatives. Ann Int Med 1986, 105 883-885
31. Giaffer MH, Holsworth CD. Effects of an elemental diet on the the faecal ‡lora of patients with Crohn’s disease. 9and J Gastroenterol 1989; 24(suppl): S148.
32. Bennett JD Use of a-tocopherylquinone in the treatment of ulcerative colitis. Gut
33. Gottschall E. Food and the Gut Reaction. Kirkton, Ontario, The Kirkton Press 1986.
34. McCann M. J Allergy Clin Immunol, 1993 (In Press).
35. Inman RD. Reactive arthritis, Reiter’s syndrome, and enteric pathogens. Infections in The Rheumatic Diseases. In: Espinoza L, Goldenberg D, Arnett F, Alarcon G eds. Orlando, FL Grune & Stratton; 1988: 273-280.
36. Gransfors KF Jalkanen S, von Essen R, et al. Yersinia antigens in synovial-fluid cells from patients with reactive arthritis. N Engl J Med 1989 320:216-221.
37. Gransfors K, Jalkanen S, Lindberg AA, et al. Salmonella iipopolysaccaride in synovlal cells from patients with reactive arthritis. Lancet 1990, 1: 685-688.
38. Fox A. Role of bacterial debris in inflammatory diseases of the joint and eye APMIS 1990; 98:957-968.
39. Phillips PE. How do bacteria cause chronic arthritis? J Rheumatol 1989; 16: 1017-1019.
40. Rooney PJ, Jenkins RT, Buchanan WW. A short review of the relationship be- tween intestinal permeability and inflammatory joint disease. Clin and Exp Rheu- amatol 1990; 8:75-83.
41. Ebringer A, Cox N, Abuljadayel I, et al. Klebsiella antibodies in ankylosing spondylitis and proteus antibodies in rheumatoid arthritis. Brit J of Rheumatol 1988 27(suppl II): 72-85.
42. McGuignan LE, Prendergast JK, Geczy AF, et al. Significance of nonpathogenic cross reactive bowel flora in patients with ankylosing spondylitis. Ann Rheum Dis 1986; 45:577-571.
43. Husby G, Tsuchiya N, Schwinmmbeck PL, et al. Cross-reactive epitope with Klebslella pneumoniae nitrogenase in articular tissue of HLA-B27 + patients with ankylosing spondylitis. Arth Rheum 1989, 32:437-445.
44. Malhotra SL. Faecal urobilinogen levels and pH of stools in population groups with different incidence of cancer of the colon, and their possible role in its aetiology. J Royal Soc Med 1982, 75:709-714
45. Walker ARP, Walker BF, Walker AJ. Faecal pH, dietary fiber intake, and proneness to colon cancer in four South Afncan populations. Brit J Canc 1986; 53:489-495.
46. Rowland IR. Factors affecting metabolic activity of the intestinal microflora. Drug Metabol Rev 1988; 19:243-261.
47. Rowland IR, Mallett AK. Dietary fiber and the gut microflora -their effects on toxicity. In: Chambers PL, Gehring P, Sakai F, eds, Amsterdam. New Concepts and Developments in Toxicology, 1986: 125-138.
48. Freudenheim J, Graham S, Horvath P. Risks associated with source of flber and fiber components in cancer of the colon and rectum. Canc Res 1990; 50:3295-3300.
49. DeCosse JJ, Miller HH, Lesser ML. Effect of wheat fiber and vltamins C and E on rectal polyps in patients with familial adenomatous polyps. J Natl Canc Inst 1989; 81:1290-1297.
50. Alberts D, Einspahr J, Rees-McGee S. Effects of dietary wheat bran fiber on rectal epithelial cell proliferation in patients with resection for colorectal cancers. J Natl Canc Inst 1990; 82:1280-1285.
51. Heitman DW, Cameron IL. Reduction of colon cancer risk by dietary cellulose supplementation. J Natl Canc Inst 1990; 82:1154-1155.
52. Mitsuoka T, Hidaka H, Eida T. Effect of fructo-oligosaccharides on intestinal microflora. Die Nahrung 1987; 31:427436.
53. Guggenbichler JP, Allerberger F, Hofstotter H, Dierich MP. Oral therapy for acute diarrhea. N Eng J Med 1991; 324:1672-1673.
54. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1989; 1:1156-1160. 55. Ayebo AD, Angelo IA and Shahani KM. Effect of ingesting acidophilus milk upon fecal flora and enzyme activity in humans. Milchwissenschaft 1980; 35:730-733. 56. Gorbach SL. Lactic acid bacteria and human health. Ann Med 1990; 22:37-41.
57. Siitonen S, Vapaatalo H, Salminen S, et al. Effect of Lactobaclllus GG yogurt in prevention of antibiotic associated diarrhoea. Ann Med 1990; 22:57-59.
58. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travelers’ diarrhoea by Lactobacillus GG. Ann Med 1990; 22:53-56.
59. Mitsuoka T. Bifidobacteria and their role in human health. J Ind Microbiol 1990; 6:263-268.
60. Yabbara KF, Juffali F, Matossian RM. Bacillus laterosporus endopthalmitis. Arch Ophthalmol 1977; 95:2187-2189.
61. Okube M, Inoue K, Umetani N, et al. Lupus nephropathy in New Zealand Fl hybrid mice treated by ( – )15-deoxyspergualin. Kidney Intl 1988; 34:467-473.
62. Umezawa K, Takeuchi T. Spergualin: a new antitumor antibiotic. Biomed Pharmacotherapy 1987; 41:227-232.
63. Shoji J, Sakazaki R, Wakisaka Y, et al. Isolation of a new antibiotic, lat- erosporamine. Studies on antibiotics from the genus Bacillus Xlll. J Antiblotlcs (Tokyo) 1976; 29:390-393.
64. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospectlve study. Gastroenterol 1989; 96:981-988.
65. Castex F, Corthier G, Jouvert S, et al. Prevention of Clostridium difflcile-induced experimental pseudomembranous colitis by Saccharomyces boulardii: a scanning electron microscopic and microbiological study. J Gen Microbiol 1990; 136:1085-1089.
66. Buts J-P, Bernasconi P, Vaerman J-P, Dive C. Stimulation of secretory IgA and secretory component of immunoglobulins sn small mtestme of rats treated withSaccharomyces boulardii. Dig Dis 9i 1990: 35:251-256.
67. Klayman DL. Qinghaosu (Artemisinin): an antimalarial drug from China. Science 1985, 228.1049-1055.
68. Levander OA, Ager A, Morris VC, May RG. Qinghaosu, dietary vitamin E, selenium and cod-liver oil: effect on the susceptibility of mice to the malarial parasite Plasmodium yoelii. Am J Clin Nutr 1989; 50:346-352.